Aptose Biosciences (NASDAQ:APTO) Price Target Raised to $6.00

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) had its price objective raised by HC Wainwright from $2.00 to $6.00 in a research report released on Friday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other equities research analysts also recently commented on APTO. StockNews.com started coverage on Aptose Biosciences in a report on Thursday. They issued a “sell” rating for the company. Alliance Global Partners raised Aptose Biosciences to a “strong-buy” rating in a research note on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Aptose Biosciences presently has an average rating of “Moderate Buy” and an average target price of $112.00.

Aptose Biosciences Stock Performance

APTO opened at $3.32 on Friday. The company has a fifty day moving average price of $4.57 and a two-hundred day moving average price of $7.50. The firm has a market capitalization of $7.11 million, a PE ratio of -1.12 and a beta of 1.14. Aptose Biosciences has a 52 week low of $2.39 and a 52 week high of $51.61.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp lifted its holdings in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 75.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 703,384 shares of the biotechnology company’s stock after purchasing an additional 301,634 shares during the quarter. Sigma Planning Corp owned 1.17% of Aptose Biosciences worth $158,000 at the end of the most recent quarter. Institutional investors and hedge funds own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.